Literature DB >> 10807654

Contractile responses to human urotensin-II in rat and human pulmonary arteries: effect of endothelial factors and chronic hypoxia in the rat.

M R MacLean1, D Alexander, A Stirrat, M Gallagher, S A Douglas, E H Ohlstein, I Morecroft, K Polland.   

Abstract

Responses to human urotensin-II (hU-II) were investigated in human and rat pulmonary arteries. Rat pulmonary arteries: hU-II was a potent vasoconstrictor of main pulmonary arteries (2 - 3 mm i.d.) (pEC(50), 8.55+/-0.08, n=21) and was approximately 4 fold more potent than endothelin-1 [ET-1] (P<0.01), although its E(max) was considerably less (approximately 2.5 fold, P<0.001). The potency of hU-II increased 2.5 fold with endothelium removal (P<0.05) and after raising vascular tone with ET-1 (P<0.01). E(max) was enhanced approximately 1.5 fold in the presence of N(omega)-nitro-L-arginine methylester (L-NAME, 100 microM, P<0.01) and approximately 2 fold in vessels from pulmonary hypertensive rats exposed to 2 weeks chronic hypoxia (P<0.05). hU-II did not constrict smaller pulmonary arteries. Human pulmonary arteries ( approximately 250 microm i.d.): in the presence of L-NAME, 3 out of 10 vessels contracted to hU-II and this contraction was highly variable. hU-II is, therefore, a potent vasoconstrictor of rat main pulmonary arteries and this response is increased by endothelial factors, vascular tone and onset of pulmonary hypertension. Inhibition of nitric oxide synthase uncovers contractile responses to hU-II in human pulmonary arteries.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10807654      PMCID: PMC1572074          DOI: 10.1038/sj.bjp.0703314

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  13 in total

1.  5-Hydroxytryptamine receptors mediating vasoconstriction in pulmonary arteries from control and pulmonary hypertensive rats.

Authors:  M R MacLean; G Sweeney; M Baird; K M McCulloch; M Houslay; I Morecroft
Journal:  Br J Pharmacol       Date:  1996-11       Impact factor: 8.739

2.  Urotensin II is the endogenous ligand of a G-protein-coupled orphan receptor, SENR (GPR14).

Authors:  M Mori; T Sugo; M Abe; Y Shimomura; M Kurihara; C Kitada; K Kikuchi; Y Shintani; T Kurokawa; H Onda; O Nishimura; M Fujino
Journal:  Biochem Biophys Res Commun       Date:  1999-11       Impact factor: 3.575

3.  Complex effects of Gillichthys urotensin II on rat aortic strips.

Authors:  A Gibson
Journal:  Br J Pharmacol       Date:  1987-05       Impact factor: 8.739

4.  Human urotensin-II is a potent vasoconstrictor and agonist for the orphan receptor GPR14.

Authors:  R S Ames; H M Sarau; J K Chambers; R N Willette; N V Aiyar; A M Romanic; C S Louden; J J Foley; C F Sauermelch; R W Coatney; Z Ao; J Disa; S D Holmes; J M Stadel; J D Martin; W S Liu; G I Glover; S Wilson; D E McNulty; C E Ellis; N A Elshourbagy; U Shabon; J J Trill; D W Hay; E H Ohlstein; D J Bergsma; S A Douglas
Journal:  Nature       Date:  1999-09-16       Impact factor: 49.962

5.  Human urotensin-II is a potent vasoactive peptide: pharmacological characterization in the rat, mouse, dog and primate.

Authors:  S A Douglas; D J Ashton; C F Sauermelch; R W Coatney; D H Ohlstein; M R Ruffolo; E H Ohlstein; N V Aiyar; R N Willette
Journal:  J Cardiovasc Pharmacol       Date:  2000-11       Impact factor: 3.105

6.  Influence of applied tension and nitric oxide on responses to endothelins in rat pulmonary resistance arteries: effect of chronic hypoxia.

Authors:  M R MacLean; K M McCulloch
Journal:  Br J Pharmacol       Date:  1998-03       Impact factor: 8.739

Review 7.  Pulmonary hypertension, anorexigens and 5-HT: pharmacological synergism in action?

Authors:  M R MacLean
Journal:  Trends Pharmacol Sci       Date:  1999-12       Impact factor: 14.819

8.  Reduced expression of endothelial nitric oxide synthase in the lungs of patients with pulmonary hypertension.

Authors:  A Giaid; D Saleh
Journal:  N Engl J Med       Date:  1995-07-27       Impact factor: 91.245

9.  Contraction of major artery segments of rat by fish neuropeptide urotensin II.

Authors:  H Itoh; Y Itoh; J Rivier; K Lederis
Journal:  Am J Physiol       Date:  1987-02

10.  Growth of the heart and lungs in hypoxic rodents: a model of human hypoxic disease.

Authors:  C Hunter; G R Barer; J W Shaw; E J Clegg
Journal:  Clin Sci Mol Med       Date:  1974-03
View more
  37 in total

1.  Differential vasoconstrictor activity of human urotensin-II in vascular tissue isolated from the rat, mouse, dog, pig, marmoset and cynomolgus monkey.

Authors:  S A Douglas; A C Sulpizio; V Piercy; H M Sarau; R S Ames; N V Aiyar; E H Ohlstein; R N Willette
Journal:  Br J Pharmacol       Date:  2000-12       Impact factor: 8.739

Review 2.  Cardiovascular actions of human urotensin II--considerations for hypertension.

Authors:  Fraser D Russell; Peter Molenaar
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2004-02-19       Impact factor: 3.000

3.  Protein expression of urotensin II, urotensin-related peptide and their receptor in the lungs of patients with lymphangioleiomyomatosis.

Authors:  Arnold S Kristof; Zhipeng You; Yin-Shan Han; Adel Giaid
Journal:  Peptides       Date:  2010-04-28       Impact factor: 3.750

Review 4.  G Protein-coupled Receptor Biased Agonism.

Authors:  Sima Y Hodavance; Clarice Gareri; Rachel D Torok; Howard A Rockman
Journal:  J Cardiovasc Pharmacol       Date:  2016-03       Impact factor: 3.105

5.  Increased plasma levels of endothelin-1 and urotensin-II in patients with coronary heart disease.

Authors:  San Bao Chai; Xue Min Li; Yong Zheng Pang; Yong Fen Qi; Chao Shu Tang
Journal:  Heart Vessels       Date:  2010-03-26       Impact factor: 2.037

6.  Urotensin II is raised in children with congenital heart disease.

Authors:  C M Simpson; D J Penny; C F Stocker; L S Shekerdemian
Journal:  Heart       Date:  2005-11-24       Impact factor: 5.994

7.  Cardiostimulant effects of urotensin-II in human heart in vitro.

Authors:  F D Russell; P Molenaar; D M O'Brien
Journal:  Br J Pharmacol       Date:  2001-01       Impact factor: 8.739

Review 8.  Cellular Pathways Promoting Pulmonary Vascular Remodeling by Hypoxia.

Authors:  Larissa A Shimoda
Journal:  Physiology (Bethesda)       Date:  2020-07-01

9.  Depressor and regionally-selective vasodilator effects of human and rat urotensin II in conscious rats.

Authors:  S M Gardiner; J E March; P A Kemp; A P Davenport; T Bennett
Journal:  Br J Pharmacol       Date:  2001-04       Impact factor: 8.739

10.  Vasoconstrictive effects of endothelin-1, endothelin-3, and urotensin II in isolated perfused human lungs and isolated human pulmonary arteries.

Authors:  R T Bennett; R D Jones; A H Morice; C F C Smith; M E Cowen
Journal:  Thorax       Date:  2004-05       Impact factor: 9.139

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.